Does biomarker information impact breast cancer patients’ preferences and physician recommendation for adjuvant chemotherapy?

Ann H. Partridge, Karen Sepucha, Anne O’Neill, Kathy Miller, Emily Baker, Chau T. Dang, Donald W. Northfelt, George W. Sledge, Bryan Schneider

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: This study aimed to examine how biomarker information would impact patients’ preferences and physicians’ recommendations for adjuvant breast cancer therapy. Methods: At the 18-month follow-up, participants in a large, double-blind randomized controlled trial of adjuvant chemotherapy with bevacizumab or placebo (E5103) were surveyed about their preferred treatment (either chemotherapy A alone or chemotherapy A+B) in two hypothetical scenarios: (1) without biomarker information; and (2) after learning that they tested positive for a “B-receptor” which modestly increased both the benefit and toxicity expected with chemotherapy A+B. We performed a cross-sectional analysis of the prospectively collected survey data and used the McNemar’s test to examine changes in treatment preferences. A one-time survey of clinical investigators who enrolled patients on the trial evaluated physician recommendations in response to the same biomarker information. Results: 439 patients completed both scenarios on 18-month survey. Most participants preferred A+B in both scenario 1 and 2 (77 and 76% respectively). The increase in benefit and toxicity associated with the positive biomarker information in scenario 2 led 60/439 (14%) of patients to switch their treatment preference. The corresponding physician survey revealed that most physicians chose regimen A+B in scenario 1 (77%), and moreso after the biomarker information was available in scenario 2 (84%). Conclusions: Information about a positive biomarker indicating increased benefit and toxicity from additional chemotherapy did not change many participants’ preferred treatment. The majority preferred the most effective course in both scenarios. Similarly, most investigators discounted increased toxicity and valued increased benefit. Parent Trial Registration: NCT00433511

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalBreast Cancer Research and Treatment
DOIs
StateAccepted/In press - Jun 23 2017

Fingerprint

Patient Preference
Adjuvant Chemotherapy
Biomarkers
Breast Neoplasms
Physicians
Drug Therapy
Research Personnel
Therapeutics
Randomized Controlled Trials
Cross-Sectional Studies
Placebos
Learning
Surveys and Questionnaires

Keywords

  • Adjuvant therapy
  • Biomarkers
  • Breast cancer
  • Patient preferences
  • Risk
  • Toxicity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Does biomarker information impact breast cancer patients’ preferences and physician recommendation for adjuvant chemotherapy? / Partridge, Ann H.; Sepucha, Karen; O’Neill, Anne; Miller, Kathy; Baker, Emily; Dang, Chau T.; Northfelt, Donald W.; Sledge, George W.; Schneider, Bryan.

In: Breast Cancer Research and Treatment, 23.06.2017, p. 1-9.

Research output: Contribution to journalArticle

Partridge, Ann H. ; Sepucha, Karen ; O’Neill, Anne ; Miller, Kathy ; Baker, Emily ; Dang, Chau T. ; Northfelt, Donald W. ; Sledge, George W. ; Schneider, Bryan. / Does biomarker information impact breast cancer patients’ preferences and physician recommendation for adjuvant chemotherapy?. In: Breast Cancer Research and Treatment. 2017 ; pp. 1-9.
@article{72dd4f35e7f741f3b67fcdb0ae3f840a,
title = "Does biomarker information impact breast cancer patients’ preferences and physician recommendation for adjuvant chemotherapy?",
abstract = "Purpose: This study aimed to examine how biomarker information would impact patients’ preferences and physicians’ recommendations for adjuvant breast cancer therapy. Methods: At the 18-month follow-up, participants in a large, double-blind randomized controlled trial of adjuvant chemotherapy with bevacizumab or placebo (E5103) were surveyed about their preferred treatment (either chemotherapy A alone or chemotherapy A+B) in two hypothetical scenarios: (1) without biomarker information; and (2) after learning that they tested positive for a “B-receptor” which modestly increased both the benefit and toxicity expected with chemotherapy A+B. We performed a cross-sectional analysis of the prospectively collected survey data and used the McNemar’s test to examine changes in treatment preferences. A one-time survey of clinical investigators who enrolled patients on the trial evaluated physician recommendations in response to the same biomarker information. Results: 439 patients completed both scenarios on 18-month survey. Most participants preferred A+B in both scenario 1 and 2 (77 and 76{\%} respectively). The increase in benefit and toxicity associated with the positive biomarker information in scenario 2 led 60/439 (14{\%}) of patients to switch their treatment preference. The corresponding physician survey revealed that most physicians chose regimen A+B in scenario 1 (77{\%}), and moreso after the biomarker information was available in scenario 2 (84{\%}). Conclusions: Information about a positive biomarker indicating increased benefit and toxicity from additional chemotherapy did not change many participants’ preferred treatment. The majority preferred the most effective course in both scenarios. Similarly, most investigators discounted increased toxicity and valued increased benefit. Parent Trial Registration: NCT00433511",
keywords = "Adjuvant therapy, Biomarkers, Breast cancer, Patient preferences, Risk, Toxicity",
author = "Partridge, {Ann H.} and Karen Sepucha and Anne O’Neill and Kathy Miller and Emily Baker and Dang, {Chau T.} and Northfelt, {Donald W.} and Sledge, {George W.} and Bryan Schneider",
year = "2017",
month = "6",
day = "23",
doi = "10.1007/s10549-017-4338-x",
language = "English (US)",
pages = "1--9",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",

}

TY - JOUR

T1 - Does biomarker information impact breast cancer patients’ preferences and physician recommendation for adjuvant chemotherapy?

AU - Partridge, Ann H.

AU - Sepucha, Karen

AU - O’Neill, Anne

AU - Miller, Kathy

AU - Baker, Emily

AU - Dang, Chau T.

AU - Northfelt, Donald W.

AU - Sledge, George W.

AU - Schneider, Bryan

PY - 2017/6/23

Y1 - 2017/6/23

N2 - Purpose: This study aimed to examine how biomarker information would impact patients’ preferences and physicians’ recommendations for adjuvant breast cancer therapy. Methods: At the 18-month follow-up, participants in a large, double-blind randomized controlled trial of adjuvant chemotherapy with bevacizumab or placebo (E5103) were surveyed about their preferred treatment (either chemotherapy A alone or chemotherapy A+B) in two hypothetical scenarios: (1) without biomarker information; and (2) after learning that they tested positive for a “B-receptor” which modestly increased both the benefit and toxicity expected with chemotherapy A+B. We performed a cross-sectional analysis of the prospectively collected survey data and used the McNemar’s test to examine changes in treatment preferences. A one-time survey of clinical investigators who enrolled patients on the trial evaluated physician recommendations in response to the same biomarker information. Results: 439 patients completed both scenarios on 18-month survey. Most participants preferred A+B in both scenario 1 and 2 (77 and 76% respectively). The increase in benefit and toxicity associated with the positive biomarker information in scenario 2 led 60/439 (14%) of patients to switch their treatment preference. The corresponding physician survey revealed that most physicians chose regimen A+B in scenario 1 (77%), and moreso after the biomarker information was available in scenario 2 (84%). Conclusions: Information about a positive biomarker indicating increased benefit and toxicity from additional chemotherapy did not change many participants’ preferred treatment. The majority preferred the most effective course in both scenarios. Similarly, most investigators discounted increased toxicity and valued increased benefit. Parent Trial Registration: NCT00433511

AB - Purpose: This study aimed to examine how biomarker information would impact patients’ preferences and physicians’ recommendations for adjuvant breast cancer therapy. Methods: At the 18-month follow-up, participants in a large, double-blind randomized controlled trial of adjuvant chemotherapy with bevacizumab or placebo (E5103) were surveyed about their preferred treatment (either chemotherapy A alone or chemotherapy A+B) in two hypothetical scenarios: (1) without biomarker information; and (2) after learning that they tested positive for a “B-receptor” which modestly increased both the benefit and toxicity expected with chemotherapy A+B. We performed a cross-sectional analysis of the prospectively collected survey data and used the McNemar’s test to examine changes in treatment preferences. A one-time survey of clinical investigators who enrolled patients on the trial evaluated physician recommendations in response to the same biomarker information. Results: 439 patients completed both scenarios on 18-month survey. Most participants preferred A+B in both scenario 1 and 2 (77 and 76% respectively). The increase in benefit and toxicity associated with the positive biomarker information in scenario 2 led 60/439 (14%) of patients to switch their treatment preference. The corresponding physician survey revealed that most physicians chose regimen A+B in scenario 1 (77%), and moreso after the biomarker information was available in scenario 2 (84%). Conclusions: Information about a positive biomarker indicating increased benefit and toxicity from additional chemotherapy did not change many participants’ preferred treatment. The majority preferred the most effective course in both scenarios. Similarly, most investigators discounted increased toxicity and valued increased benefit. Parent Trial Registration: NCT00433511

KW - Adjuvant therapy

KW - Biomarkers

KW - Breast cancer

KW - Patient preferences

KW - Risk

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=85021203261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021203261&partnerID=8YFLogxK

U2 - 10.1007/s10549-017-4338-x

DO - 10.1007/s10549-017-4338-x

M3 - Article

SP - 1

EP - 9

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

ER -